We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Breakthrough Technology Characterizes Immune Response

By LabMedica International staff writers
Posted on 16 Nov 2015
Assays enabling the identification and enumeration of antigen-specific T cells are critical tools in characterizing immune responses and harnessing T cell function for treatment of numerous diseases including cancer.

A novel multiplex assay has been developed that combines conventional immune monitoring techniques and immune receptor repertoire sequencing to enable identification of T cells specific to large numbers of antigens simultaneously. More...


Scientists at Adaptive Biotechnologies (South San Francisco, CA, USA) multiplexed 30 different antigens and identified 427 antigen-specific clonotypes from five individuals with frequencies as low as one per million T cells. The clonotypes identified were validated several ways including repeatability, concordance with published clonotypes, and high correlation with Enzyme-Linked ImmunoSpot (ELISPOT).

Antigen-specific T cells were identified using one of two approaches: either by dextramer binding or by CD137 upregulation following overnight incubation with mixtures of peptides. Dextramer-specific T cells were identified by incubating peripheral blood mononuclear cells (PBMCs) with pools of eight dextramers. The new assay was named MIRA for Multiplexed Identification of T cell Receptor Antigen specificity.

The ELISPOT results for four antigens were independently generated for each donor. ELISPOT measures the total number of antigen-specific T cells secreting a particular cytokine. If all antigen-specific T cells secrete the cytokine measured by ELISPOT then results would be analogous to the sum frequency of antigen-specific clonotypes identified by MIRA. The scientists compared IFN-γ ELISPOT results with the sum frequency of antigen-specific clonotypes from each donor. There was a high correlation between results from both assays and MIRA readily detected antigen-specific clonotypes below 1 in 100,000 PBMCs, below estimates of the limit of detection for ELISPOT of around 4 spots per 100,000 PBMCs.

Harlan Robins, PhD, Chief Scientific Officer and Co-Founder at Adaptive Biotechnologies, said, “With this new multiplex technology we now have the ability to assign antigen-specificity to T cell receptors (TCR) sequences at a massive scale. Combined with our first-in-class technology for pairing TCR alpha and beta chain sequences at high throughput, we now have the tools needed for efficient identification of functional immune receptors, which may lead to tremendous advancements in biomarker discovery and therapeutic development.” The study was published on October 28, 2015, in the journal Public Library of Science ONE.

Related Links:

Adaptive Biotechnologies 



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.